IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

被引：0

作者：

Trojan, J. ^{[1
]}

Chow, P. ^{[2
,3
]}

Chen, M. ^{[4
]}

Cheng, A-L ^{[5
,6
]}

Kaseb, A. ^{[7
]}

Kudo, M. ^{[8
]}

Lee, H. C. ^{[9
]}

Yopp, A. ^{[10
]}

Zhou, J. ^{[11
]}

Wang, L. ^{[12
]}

Wen, X. ^{[13
]}

Heo, J. ^{[14
,15
]}

Tak, W-Y ^{[16
]}

Nakamura, S. ^{[17
]}

Numata, K. ^{[18
]}

Uguen, T. ^{[19
]}

Hsieh, D. ^{[10
]}

Cha, E. ^{[20
]}

Hack, S. P. ^{[20
]}

Lian, Q. ^{[20
]}

Spahn, J. ^{[20
]}

Wu, C. ^{[21
]}

Qin, S. ^{[22
]}

机构：

[1] Univ Klinikum Frankfurt, Frankfurt, Germany

[2] Natl Canc Ctr Singapore, Singapur, Singapore

[3] Duke NUS Med Sch, Singapur, Singapore

[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[5] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] MD Anderson Canc Ctr, Houston, TX USA

[8] Kindai Univ, Osaka, Japan

[9] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[10] UT Southwestern Med Ctr, Dallas, TX USA

[11] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[13] 1st Hosp Jilin Univ, Jilin, Jilin, Peoples R China

[14] Pusan Natl Univ, Coll Med, Busan, South Korea

[15] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea

[16] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea

[17] Himeji Red Cross Hosp, Himeji, Hyogo, Japan

[18] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan

[19] Hosp Pontchaillou, Rennes, France

[20] Genentech Inc, San Francisco, CA USA

[21] Roche Holding Ltd, Shanghai, Peoples R China

[22] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P687

引用

页码：239 / 239

页数：1

共 50 条

[1] Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation
Yopp, Adam Charles
Cheng, Ann-Lii
Kaseb, Ahmed Omar
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S19 - S19
[2] Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Kudo, Masatoshi
Chen, Minshan
Chow, Pierce K. H.
Kaseb, Ahmed Omar
Lee, Han Chu
Yopp, Adam C.
Becker, Lars
Painter, Sairy Hernandez
Kovic, Bruno
Lian, Qinshu
Ma, Ning
Wu, Chun
Qin, Shukui
Cheng, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation
Kaseb, Ahmed
Chen, Minshan
Chow, Pierce
Kudo, Masatoshi
Lee, Han Chu
Yopp, Adam
Becker, Lars
Hernandez, Sairy
Kovic, Bruno
Lian, Qinshu
Ma, Ning
Wu, Chun
Qin, Shukui
Cheng, Ann-Lii
JOURNAL OF HEPATOLOGY, 2023, 78 : S9 - S10
[4] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Yopp, A.
Kudo, M.
Chen, M.
Cheng, A-L.
Kaseb, A. O.
Lee, H. C.
Qin, S.
Cha, E.
Hack, S. P.
Lian, Q.
Spahn, J.
Wu, C.
Chow, P.
ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230
[5] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial
Qin, Shukui
Chen, Minshan
Cheng, Ann-Lii
Kaseb, Ahmed
Kudo, Masatoshi
Lee, Han Chu
Yopp, Adam C.
Zhou, Jian
Wang, Lu
Wen, Xiaoyu
Heo, Jeong
Tak, Won Young
Nakamura, Shinichiro
Numata, Kazushi
Uguen, Thomas
Hsiehchen, David
Cha, Edward
Hack, Stephen P.
Lian, Qinshu
Ma, Ning
Spahn, Jessica H.
Wang, Yulei
Wu, Chun
Chow, Pierce K. H.
LANCET, 2023, 402 (10415): : 1835 - 1847
[6] IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
Hack, Stephen P.
Spahn, Jessica
Chen, Minshan
Cheng, Ann-Lii
Kaseb, Ahmed
Kudo, Masatoshi
Lee, Han Chu
Yopp, Adam
Chow, Pierce
Qin, Shukui
FUTURE ONCOLOGY, 2020, 16 (15) : 975 - 989
[7] IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation (vol 16, pg 975, 2020)
Hack, S. P.
FUTURE ONCOLOGY, 2020, 16 (29) : 2371 - 2371
[8] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection
Knox, J.
Cheng, A.
Cleary, S.
Galle, P.
Kokudo, N.
Lencioni, R.
Park, J.
Zhou, J.
Mann, H.
Morgan, S.
Liu, X.
Chin, S.
Vlahovic, G.
Fan, J.
ANNALS OF ONCOLOGY, 2019, 30
[9] Atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study
Ducreux, Michel
Zhu, Andrew
Qin, Shukui
Ikeda, Masafumi
Kim, Tae-You
Lim, Ho Yeong
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Verret, Wendy
Xu, Zhen
Hernandez, Sairy
Liu, Juan
Shao, Hui
Huang, Chen
Cheng, Ann-Lii
Finn, Richard
Galle, Peter
JOURNAL OF HEPATOLOGY, 2020, 73 : S121 - S121
[10] A phase II study of tislelizumab (TIS) plus sitravatinib as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgical resection
Liu, L-X.
Peng, T.
Liu, C.
Wang, J.
Zhu, G.
Zhang, X.
ANNALS OF ONCOLOGY, 2022, 33 : S1444 - S1444

← 1 2 3 4 5 →